Form 4: CARGO Therapeutics Director Disposes Options Post-Merger

A director of CARGO Therapeutics, Abraham Bassan, disposed of stock options following the company's acquisition by Concentra Biosciences.

Summary

• Abraham Bassan, a director of CARGO Therapeutics, Inc. (CRGX), reported the disposition of 25,000 stock options.
• This disposition occurred on August 19, 2025, following the completion of the merger between CARGO Therapeutics and Concentra Biosciences, LLC.
• The merger involved a tender offer completed on August 18, 2025, where shares were acquired for $4.379 per share in cash plus one contingent value right (CVR).
• Each outstanding stock option, including Bassan's, became fully vested and was converted into cash and CVRs.
• Bassan's options, with an exercise price of $4.35 per share, resulted in a cash payment of $725.00 and 25,000 CVRs.

Sentiment

Score: 7

Explanation: The filing reports a standard transaction related to a completed merger, indicating a successful exit for the company and a payout for option holders. The CVRs offer potential future upside.

Positives

• The reporting person's stock options became fully vested and exercisable due to the merger.
• The options were converted into cash and contingent value rights (CVRs), providing immediate liquidity and potential future value.
• The exercise price of the options ($4.35) was below the cash offer price ($4.379), resulting in a positive cash payout for the option holder.

Negatives

• The reporting person no longer holds derivative securities in CARGO Therapeutics, Inc. following the merger.
• The company is now a wholly-owned subsidiary of Concentra Biosciences, LLC, meaning its common stock is no longer publicly traded.

Future Outlook

NA

Industry Context

This filing reflects the final stages of an acquisition in the biotechnology or pharmaceutical sector, where a smaller company (CARGO Therapeutics) is acquired by a larger entity (Concentra Biosciences). Such mergers are common for consolidating intellectual property, pipelines, or market share.

Comparison to Industry Standards

• The acquisition price of $4.379 per share plus a CVR is specific to this transaction and would require detailed financial models to compare against industry benchmarks for similar biotech acquisitions.
• The use of Contingent Value Rights (CVRs) is a common mechanism in biotech mergers, especially when there is uncertainty around future clinical milestones or regulatory approvals, allowing sellers to participate in potential upside.
• The premium paid (or lack thereof, given the small difference between option exercise price and offer price) would need to be assessed against typical acquisition premiums in the biotech sector, which often range from 30% to 100% or more over pre-announcement stock prices, depending on the target's pipeline and stage of development.

Stakeholder Impact

• Shareholders: Received $4.379 cash per share plus one CVR, indicating a liquidity event and potential future value.
• Option Holders (like Bassan): Received cash and CVRs for their vested options, providing a payout.
• Company (CARGO Therapeutics): Now a wholly-owned subsidiary, no longer publicly traded.

Key Dates

Recommendation

The company, CARGO Therapeutics, Inc., has been acquired by Concentra Biosciences, LLC and is no longer publicly traded. Therefore, traditional buy/sell/hold recommendations for its common stock are no longer applicable. For investors who received Contingent Value Rights (CVRs) as part of the merger consideration, the recommendation would be to hold the CVRs, as their value is contingent on future milestones and they are non-transferable.

Keywords

CARGO Therapeutics, CRGX, Concentra Biosciences, Merger, Acquisition, Stock Option, Form 4, Insider Trading, Contingent Value Right, CVR, Abraham Bassan